INJECTION

Nyvepria™

pegfilgrastim-apgf

Pfizer

An FDA-approved biosimilar to Neulasta® (pegfilgrastim)[1*†]

A PFIZER BIOSIMILAR BUILT ON EXPERIENCE

Part of the largest oncology biosimilars portfolio[2]

NYVEPRIA product and reimbursement information for your practice

- Indication
- Pfizer Oncology Together™
- Payer Coverage by Region
- Important Safety Information
- Ordering
- References

Learn more about NYVEPRIA

SELECTED SAFETY INFORMATION

Contraindications

- NYVEPRIA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis

Warnings and Precautions

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
- Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving NYVEPRIA

*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.

†NYVEPRIA does not have a designation of interchangeability with Neulasta.

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

NYVEPRIA™ (pegfilgrastim-apgf) Is FDA Approved for the Eligible Indication of Neulasta® (pegfilgrastim)[1]

INDICATION

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Acute Respiratory Distress Syndrome (ARDS)

- ARDS can occur in patients receiving pegfilgrastim products
- Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving NYVEPRIA
- Discontinue NYVEPRIA in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
- The majority of reported events occurred upon initial exposure
- Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment
- Permanently discontinue NYVEPRIA in patients with serious allergic reactions
- Do not administer NYVEPRIA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

NYVEPRIA™ (pegfilgrastim-apgf) Payer Coverage*†

National and State Coverage Rates[3]

Individual state rates represent the percentage of commercial lives where NYVEPRIA™ (pegfilgrastim-apgf) is covered at parity or at an advantage to Neulasta® (pegfilgrastim)*†

Click on a region to learn more



National access rates at **parity** or **better**, compared to Neulasta

32%
of commercially insured patients have access to NYVEPRIA nationwide*†

67%
of Medicare lives covered nationwide, including managed Medicare*†

*As of April 2022.

†The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

NYVEPRIA™ (pegfilgrastim-apgf) Payer Coverage*†

Northeastern United States



Individual state rates represent the percentage of commercial lives where NYVEPRIA™ (pegfilgrastim-apgf) is covered at parity or at an advantage to Neulasta® (pegfilgrastim)*†

*As of April 2022.

†The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

NYVEPRIA™ (pegfilgrastim-apgf) Payer Coverage*†

Southern United States



Individual state rates represent the percentage of commercial lives where NYVEPRIA™ (pegfilgrastim-apgf) is covered at parity or at an advantage to Neulasta® (pegfilgrastim)*†

*As of April 2022.

†The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

NYVEPRIA™ (pegfilgrastim-apgf) Payer Coverage*†

Western United States



Individual state rates represent the percentage of commercial lives where NYVEPRIA™ (pegfilgrastim-apgf) is covered at parity or at an advantage to Neulasta® (pegfilgrastim)*†

*As of April 2022.

†The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

NYVEPRIA™ (pegfilgrastim-apgf) Payer Coverage*†

Midwestern United States



Individual state rates represent the percentage of commercial lives where NYVEPRIA™ (pegfilgrastim-apgf) is covered at parity or at an advantage to Neulasta® (pegfilgrastim)*†

*As of April 2022.

†The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

An FDA-approved Biosimilar to Neulasta® (pegfilgrastim)[1]

NYVEPRIA™ (pegfilgrastim-apgf) Injection for Subcutaneous Use

Ordering NYVEPRIA—What You Need to Know[1,3,4]	
Unit of Sale	6 mg/0.6 mL
Unit of Sale NDC	0069-0324-01
Unit of Sale Quantity	1 prefilled syringe
Unit of Sale List Price*	$3,925
HCPCS Code	**Descriptor**
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (NYVEPRIA), 0.5 mg

340B pass-through status effective April 1, 2021[4,5]

*As of May 2022.

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Glomerulonephritis

- Glomerulonephritis has occurred in patients receiving pegfilgrastim products
- The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy
- Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products
- If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of NYVEPRIA

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

Pfizer Oncology together™

Making your patients' support needs a priority. Together.

Pfizer Oncology Together™ is a personalized support program to help patients and their loved ones throughout NYVEPRIA treatment. We can assist with the access and reimbursement process and help identify financial assistance options for your patients prescribed NYVEPRIA. And when your patients need support for their day-to-day challenges, we can provide them with a dedicated Care Champion who has social work experience and can connect them to resources that may help. Because when it comes to support, we're in this together.



FOR LIVE, PERSONALIZED SUPPORT
Call **1-877-744-5675** (Monday–Friday 8 AM–8 PM ET)

VISIT
PfizerOncologyTogether.com

SELECTED SAFETY INFORMATION

Warnings and Precautions (continued)

Leukocytosis

- White blood cell counts of 100 x 10^9/L or greater have been observed in patients receiving pegfilgrastim products
- Monitoring of complete blood count (CBC) during NYVEPRIA therapy is recommended

Thrombocytopenia

- Thrombocytopenia has been reported in patients receiving pegfilgrastim products
- Monitor platelet counts

Capillary Leak Syndrome (CLS)

- CLS has been reported after granulocyte-colony stimulating factor (G-CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency and severity and may be life-threatening if treatment is delayed
- Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

Important Safety Information and Indication

Contraindications

- NYVEPRIA is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis

Warnings and Precautions

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
- Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving NYVEPRIA

Acute Respiratory Distress Syndrome (ARDS)

- ARDS can occur in patients receiving pegfilgrastim products
- Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving NYVEPRIA
- Discontinue NYVEPRIA in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
- The majority of reported events occurred upon initial exposure
- Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment
- Permanently discontinue NYVEPRIA in patients with serious allergic reactions
- Do not administer NYVEPRIA to patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products

Use in Patients with Sickle Cell Disorders

- Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving pegfilgrastim products
- Discontinue NYVEPRIA if sickle cell crisis occurs

(continued on next page)

Important Safety Information and Indication (continued)

Warnings and Precautions (continued)

Glomerulonephritis

- Glomerulonephritis has occurred in patients receiving pegfilgrastim products
- The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy
- Generally, events of glomerulonephritis resolved after dose-reduction or discontinuation of pegfilgrastim products
- If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of NYVEPRIA

Leukocytosis

- White blood cell counts of 100 x 10^9/L or greater have been observed in patients receiving pegfilgrastim products
- Monitoring of complete blood count (CBC) during NYVEPRIA therapy is recommended

Thrombocytopenia

- Thrombocytopenia has been reported in patients receiving pegfilgrastim products
- Monitor platelet counts

Capillary Leak Syndrome (CLS)

- CLS has been reported after granulocyte-colony stimulating factor (G-CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration
- Episodes vary in frequency and severity and may be life-threatening if treatment is delayed
- Patients who develop symptoms of CLS should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

- The G-CSF receptor through which pegfilgrastim and filgrastim products act has been found on tumor cell lines
- The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

- MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer
- Monitor patients for signs and symptoms of MDS/AML in these settings

(continued on next page)

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

Important Safety Information and Indication (continued)

Warnings and Precautions (continued)

Aortitis

- Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and white blood cell count)
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue NYVEPRIA if aortitis is suspected

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most Common Adverse Reactions

- Bone pain
- Pain in extremity

INDICATION

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

References

1. NYVEPRIA [prescribing information]. New York, NY: Pfizer Inc.; October 2021.
2. McGowan S, Biehn B. U.S. Biosimilar Report. AmerisourceBergen. December 20, 2021. Accessed January 31, 2022. https://amerisourcebergen.com/-/media/assets/amerisourcebergen/biosimilars-page/sgs-biosimilars-usmarketlandscape-122021---final.pdf.
3. Data on file. Pfizer Inc.; New York, NY.
4. Centers for Medicare & Medicaid Services. April 2021 Update of the Hospital Outpatient Prospective Payment System (OPPS). Updated April 1, 2021.
5. Centers for Medicare & Medicaid Services. Medicare-FFS Program: Billing 340B Modifiers under the Hospital Outpatient Prospective Payments System (OPPS). April 2, 2018. Accessed March 8, 2022. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/Billing-340B-Modifiers-under-Hospital-OPPS.pdf.

NYVEPRIA is a trademark of Pfizer Inc.
Neulasta® (pegfilgrastim) is a registered trademark of Amgen Inc.

Please see Important Safety Information and Indication on pages 6-8 and full Prescribing Information, Patient Information, and Instructions for Use available at NyvepriaHCP.com.

 © 2022 Pfizer Inc. All rights reserved.